Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:56:45.236Z.
Calculation as of: 2026-10-06T15:56:45.236Z.
Quote observation: 2026-10-06T15:54:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48f0cd224d3c7dd52ecd2cde696dbbeed4cc913852df97ed5052446ca25b90ee
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$77.54M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.46M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.48M
Price/FCF Ratio
N/A
TTM Avg
786.60
3Y Avg
786.60
5Y Avg
786.60
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hyperfine, Inc. (HYPR) | $76.19M | N/A | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $76.19M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $74.43M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.45M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $83.48M | N/A | 786.60 | 786.60 | 786.60 |
| LENSAR Inc (LNSR)vs › | $82.53M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $70.44M | N/A | 1291.26 | 1291.26 | 1291.26 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
